1.8308
6.73%
+0.1208
TRACON Pharmaceuticals Inc stock is currently priced at $1.8308, with a 24-hour trading volume of 52,115.
It has seen a +6.73% increased in the last 24 hours and a +339.12% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.75 pivot point. If it approaches the $1.91 resistance level, significant changes may occur.
Previous Close:
$1.71
Open:
$1.72
24h Volume:
52,115
Market Cap:
$4.16M
Revenue:
-
Net Income/Loss:
$-3.59M
P/E Ratio:
-1.5648
EPS:
-1.17
Net Cash Flow:
$3.68M
1W Performance:
+1.96%
1M Performance:
+339.12%
6M Performance:
+1,148%
1Y Performance:
+162.97%
TRACON Pharmaceuticals Inc Stock (TCON) Company Profile
Name
TRACON Pharmaceuticals Inc
Sector
Industry
Phone
858 550 0780
Address
4350 La Jolla Village Drive, Suite 800, San Diego, CA
TRACON Pharmaceuticals Inc Stock (TCON) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-16-21 | Upgrade | BTIG Research | Neutral → Buy |
Feb-10-21 | Initiated | Maxim Group | Buy |
Dec-23-19 | Reiterated | H.C. Wainwright | Buy |
Mar-01-19 | Reiterated | Needham | Buy |
Jun-13-17 | Reiterated | Stifel | Buy |
Dec-21-16 | Initiated | Jefferies | Buy |
Feb-01-16 | Resumed | Oppenheimer | Outperform |
Jul-29-15 | Initiated | ROTH Capital | Buy |
Mar-02-15 | Reiterated | Oppenheimer | Outperform |
Mar-02-15 | Reiterated | Stifel | Buy |
Feb-24-15 | Initiated | Oppenheimer | Outperform |
Feb-24-15 | Initiated | Stifel | Buy |
View All
TRACON Pharmaceuticals Inc Stock (TCON) Latest News
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
TRACON Pharmaceuticals Announces Reverse Stock Split
GlobeNewswire Inc.
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
TRACON Pharmaceuticals Inc Stock (TCON) Financials Data
TRACON Pharmaceuticals Inc (TCON) Net Income 2024
TCON net income (TTM) was -$3.59 million for the quarter ending December 31, 2023, a +87.68% increase year-over-year.
TRACON Pharmaceuticals Inc (TCON) Cash Flow 2024
TCON recorded a free cash flow (TTM) of $3.68 million for the quarter ending December 31, 2023, a +114.00% increase year-over-year.
TRACON Pharmaceuticals Inc (TCON) Earnings per Share 2024
TCON earnings per share (TTM) was -$5.00 for the quarter ending December 31, 2023, a +82.14% growth year-over-year.
About TRACON Pharmaceuticals Inc
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):